Skip to main content
Wednesday, November 11, 2026Nov 11

Sanofi ousts CEO amid pressure over diabetes drug

FILE - In this Feb.6, 2014 file photo, CEO of Sanofi, Christopher A. Viehbacher, poses for photographers as he arrives for the annual results in Paris. The board of drug maker Sanofi has fired Viehbacher after he warned that pricing pressure on a best-selling diabetes treatment in the U.S. would hurt growth into next year. (AP Photo/Michel Euler, File)
FILE - In this Feb.6, 2014 file photo, CEO of Sanofi, Christopher A. Viehbacher, poses for photographers as he arrives for the annual results in Paris. The board of drug maker Sanofi has fired Viehbacher after he warned that pricing pressure on a best-selling diabetes treatment in the U.S. would hurt growth into next year. (AP Photo/Michel Euler, File) FILE - In this Feb.6, 2014 file photo, CEO of Sanofi, Christopher A. Viehbacher, poses for photographers as he arrives for the annual results in Paris. The board of drug maker Sanofi has fired Viehbacher after he warned that pricing pressure on a best-selling diabetes treatment in the U.S. would hurt growth into next year. (AP Photo/Michel Euler, File)

PARIS (AP) – French drugmaker Sanofi sacked its CEO Wednesday following a board room rift over the handling of one of France’s largest publicly traded companies.

Christopher Viehbacher, the first non-Frenchman to lead Sanofi, was dismissed after six years running the company that traces its roots to the early 19th century.

In a statement announcing the ouster, Sanofi’s board referred to the rift with the Canadian-German Viehbacher only obliquely, saying the company needs “a management aligning the teams, harnessing talents and focusing on execution with a close and confident cooperation with the Board.”

Viehbacher, 54, will be temporarily replaced by Sanofi chairman Serge Weinberg, 63, the one-time head of Gucci parent company PPR who was himself ousted following a rift with his board.

Sanofi’s shares more than doubled during Viehbacher’s six years at the helm as he cut costs and shifted focus to biotechnology, vaccines and over-the-counter medications. He orchestrated the $20 billion takeover of U.S. biotech firm Genzyme in 2011. But his move earlier this year to Boston from Paris, where he’d moved after taking the helm at Sanofi, raised eyebrows in France.